AR059246A1 - Compuestos heterobiciclicos de tiofeno y metodos de uso - Google Patents
Compuestos heterobiciclicos de tiofeno y metodos de usoInfo
- Publication number
- AR059246A1 AR059246A1 ARP070100391A ARP070100391A AR059246A1 AR 059246 A1 AR059246 A1 AR 059246A1 AR P070100391 A ARP070100391 A AR P070100391A AR P070100391 A ARP070100391 A AR P070100391A AR 059246 A1 AR059246 A1 AR 059246A1
- Authority
- AR
- Argentina
- Prior art keywords
- nr10r11
- aryl
- alkyl
- cr14r15
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Compuesto de formula (1) y sus sales farmacéuticamente aceptables, que son utiles para inhibir las quirosin quinasas receptoras y para tratar trastornos intermediados por éstas. Se describen métodos de uso de los compuestos de formula (1) y sus sales farmacéuticamente aceptables para el diagnostico, prevencion o tratamiento in vitro, in situ e in vivo de dichos trastornos en células de mamíferos o trastornos patologicos asociados. Reivindicacion 1: Un compuesto seleccionado de la formula (1), y sus sales farmacéuticamente aceptables, donde: X es O, S o NR10; Z2 y Z3 están independientemente seleccionados entre CR4 y N, donde unicamente uno de Z2 y Z3 es N; R1 es H, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, -C(=O)NR10R11, N- (CR14R15)tNR10R11, -NR10C(=Y)R11, -NR10C(=Y)OR11, -NR12C(=Y)NR10R11, o -NR12SO2NR10R11, o R1 es un carbociclilo C3-12, heterociclilo C2-20, arilo C6-20 o heteroarilo C1-20 monocíclico o bicíclico, donde dichos alquilo, alquenilo, alquinilo, carbociclilo, heterociclilo, arilo y heteroarilo están sustituidos opcionalmente con uno o más grupos seleccionados independientemente entre F, CI, Br, I, CN, CF3, oxo, OR10, SR10, -C(=Y)R10, -C(=Y)OR10, -C(=Y)NR10R11, -(CR14R15)n-NR10R11, - NR10C(=Y)R13, -NR10C(=Y)OR11, --NR12C(=Y)NR10R11, -NR12SO2R10, -OC(=Y)R10, -OC(=Y)OR10, -OC(=Y)NR10R11, -OS(O)2(OR10), -OP(=Y)(OR10)(OR11), -OP(OR10)(OR11), -S(O)R10, -S(O)2R10, -S(O)2NR10R11, -S(O)(OR10), -S(O)2(OR10), -SC(=Y)R10, -SC(=Y)OR10, - SC(=Y)NR10R11, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, heterociclilo C2-20, arilo C6-20 y heteroarilo C1-20, -(CR14R15)n-NR12C(=O)(CR14R15)mNR10R11, y -C(O)(CR14R15)nNR10R11; R2 y R4 son independientemente H, F, CI, Br, I, CN, -C(=Y)R10, -C(=Y)OR10, -C(=Y)NR10R11, -NR10R11, -NR10C(=Y)R11, -NR10C(=Y)OR11, -NR12C(=Y)NR10R11, -NR12SO2R10R11, -OR10, -OC(=Y)R10, -OC(=Y)OR10, -OC(=Y)NR10R11, -C(=O)NR12(CR14R15)tNR10R11, -OP(=Y)(OR10)(OR11), -OP(OR10)(OR11), -SR10, -S(O)R10, -S(O)2R10, -S(O)2NR10R11, -SC(=Y)R10, -SC(=Y)OR10, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20, o heteroarilo C1-20, donde dichos alquilo, alquenilo, alquinilo, carbociclilo, heterociclilo, arilo, y heteroarilo están sustituidos opcionalmente con uno o más grupos seleccionados independientemente entre F, CI, Br, I, OR10, y NR10R11; R3 es un carbociclilo C3-12, heterociclilo C2-20, arilo C6-20 o heteroarilo C1-20 monocíclicos o bicíclicos, donde dichos carbociclilo, heterociclilo, arilo y heteroarilo están sustituidos opcionalmente con uno o más grupos seleccionados independientemente entre F, CI, Br, I, CN, CF3, OR10, SR10, -C(=Y)R10, -C(=Y)OR10, -C(=Y)NR10R11, -NR10R11, - NR10C(=Y)R13, -NR10C(=Y)OR11, -NR12C(=Y)NR10R11, -NR12C(=Y)NR10R11, -NR12C(=O)C(=O)R10R11, -NR12C(=O)C(=O)NR10R11, -NR12C(=O)C(=O)Ora, -NR12SO2R10, -NR12C(=Y1)(CR14R15)nC(=Y2)NR10R11, -NR12C(=Y1)NR10C(=Y2)(CR14R15)nR11, - NR12C(=Y1)(CR14R15)nC(=Y2)(CR14R15)mR10, -OC(=Y)R10, -OC(=Y)OR10, -OC(=Y)NR10R11, -OS(O)2(OR10), -OP(=Y)(OR10)(OR11), -OP(OR10)(OR11), -S(O)R10, -S(O)2R10, -S(O)2NR10R11, -S(O)(OR10), -S(O)2(OR10), -SC(=Y)R10, -SC(=Y)OR10, -SC(=Y)NR10R11, alquilo C1- 12, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, heterociclilo C2-20, arilo C6-20 y heteroarilo C1-20, donde dichos alquilo, alquenilo, alquinilo, cicloalquilo, heterociclilo, arilo, y heteroarilo están sustituidos opcionalmente con uno o más grupos seleccionados independientemente entre F, CI, Br, I, OH, alquilo C1-12, oxo, NR10R11, -C(=Y)NR10R11 y(CR14R15)n-arilo; R10, R11 y R12 son independientemente H, ORa, alquilo C1-12, alquenilo C2-8, o alquinilo C2-8, o carbociclilo C3-12, heterociclilo C2-20, arilo C6-20, o heteroarilo C1-20 monocíclicos o bicíclicos donde dichos alquilo, alquenilo, alquinilo, carbociclilo, heterociclilo, arilo, y heteroarilo están sustituidos opcionalmente con uno o más grupos seleccionados independientemente entre F, CI, Br, I, SO2RC, CN, ORa, NRaRb, C(=O)NRaRb, CRaC(=O)Rb, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-20, arilo C6-20, y heteroarilo C1-20, o R10 y R11 conjuntamente con el nitrogeno al cual están unidos forman opcionalmente un anillo heterocíclico C3-20 saturado, parcialmente insaturado o totalmente insaturado que contiene opcionalmente uno o más átomos de anillos adicionales seleccionados entre N, O o S, donde dicho anillo heterocíclico está sustituido opcionalmente con uno o más grupos seleccionados independientemente entre oxo, ORa NRaRb, CF3, F, CI, Br, I, SO2Ra, C(=O)Ra, NR10C(=Y)R11, C(=Y)NR10R11, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, heterociclilo C2-20, arilo C6-20 y heteroarilo C1-20, R13 es H, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, (CR14R15)n-cicloalquilo, -(CR14R15)n-heterocicliIo, (CR14R15)n-arilo, (CR14R15)n-heteroarilo, (CR14R15)n-O-(CR14R15)m-arilo, (CR14R15)n-OR10, (CR14R15)n- NR10R11, (CR14R15)n-NR10C(=O)R11, o (CR14R15)n-NR10(SO2Me)-R11, donde dichas porciones alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, y heteroarilo están sustituidas opcionalmente con uno o más grupos seleccionados independientemente entre F, CI, Br, I, oxo, SO2RC, CN, ORa, C(=O)Ra, C(=O)ORa, NRaRb, NRaC(=O)Rb, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, heterociclilo C2-20, arilo C6-20, y heteroarilo C1-20; R14 y R15 son independientemente H, alquilo C1-12, o (CR14R15)tariIo, o R14 y R15 conjuntamente con los átomos a los cuales están unidos forman un anillo carbocíclico C3-12 saturado o parcialmente insaturado; o R10 y R15 conjuntamente con los átomos a los cuales están unidos forman un anillo heterocíclico C1-20 saturado o parcialmente insaturado que está opcionalmente sustituido con uno o más grupos seleccionados independientemente entre F, CI, Br, I, ORa, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, heterociclilo C2-20, arilo C6-20, y heteroarilo C1-20, donde dichos alquilo y arilo están sustituidos opcionalmente con uno o más grupos seleccionados independientemente entre F, CI, Br, y I, o R14 es nulo y R10 y R15 conjuntamente con los átomos a los cuales están unidos forman un anillo heteroarilo C1-20 que tiene uno o más heteroátomos; Ra y Rb son independientemente H, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20, o heteroarilo C1-20, donde dichos alquilo, alquenilo, alquinilo, carbociclilo, heterociclilo, arilo, y heteroarilo están sustituidos opcionalmente con uno o más grupos alquilo o halogeno; Rc es alquilo C1-12 o arilo C6-20, donde dichos alquilo y arilo están sustituidos opcionalmente con uno o más grupos seleccionados independientemente entre F, CI, Br, I, ORa y C(=O)NRaRb; Y, Y1 y Y2 son independientemente O o S; t es 1,2,3,4,5 o 6;y n y m son independientemente 0, 1, 2, 3, 4, 5 o 6.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76341406P | 2006-01-30 | 2006-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR059246A1 true AR059246A1 (es) | 2008-03-19 |
Family
ID=39272752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070100391A AR059246A1 (es) | 2006-01-30 | 2007-01-30 | Compuestos heterobiciclicos de tiofeno y metodos de uso |
Country Status (8)
Country | Link |
---|---|
US (1) | US8003662B2 (es) |
EP (1) | EP1989211A2 (es) |
JP (1) | JP2009526761A (es) |
CN (1) | CN101522687A (es) |
AR (1) | AR059246A1 (es) |
CA (1) | CA2636242A1 (es) |
TW (1) | TW200806675A (es) |
WO (1) | WO2008063202A2 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003201573B2 (en) * | 2002-01-22 | 2009-02-26 | Biomatera Inc. | Method of drying biodegradable polymers |
AU2006229343A1 (en) * | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency |
CA2608726C (en) | 2005-05-20 | 2013-07-09 | Methylgene Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
EP1957498B1 (en) * | 2005-05-20 | 2017-02-15 | MethylGene Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
AU2007240568A1 (en) * | 2006-04-21 | 2007-11-01 | Amgen Inc. | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use |
US20110053931A1 (en) * | 2006-06-08 | 2011-03-03 | John Gaudino | Quinoline compounds and methods of use |
JP5642963B2 (ja) * | 2006-06-30 | 2014-12-17 | スネシス ファーマシューティカルズ,インコーポレイティド | ピリジノニルpdk1阻害剤 |
AU2008236670B2 (en) * | 2007-04-05 | 2011-12-01 | Amgen Inc. | Aurora kinase modulators and method of use |
US8907091B2 (en) | 2007-08-29 | 2014-12-09 | Methylgene Inc. | Processes and intermediates for preparing fused heterocyclic kinase inhibitors |
CA2697795C (en) * | 2007-08-29 | 2016-08-16 | Methylgene Inc. | Thieno[3,2,b]pyridinyl compounds as inhibitors of protein tyrosine kinase activity |
CN101977905B (zh) | 2008-01-23 | 2014-07-02 | 百时美施贵宝公司 | 4-吡啶酮化合物及其对于癌症的用途 |
JPWO2009110415A1 (ja) | 2008-03-03 | 2011-07-14 | 武田薬品工業株式会社 | 併用剤 |
CA2717816A1 (en) * | 2008-03-05 | 2009-09-11 | Tetsuyuki Uno | Inhibitors of protein tyrosine kinase activity |
EP2257293A2 (en) * | 2008-03-06 | 2010-12-08 | Genentech, Inc. | Combination therapy with c-met and egfr antagonists |
TW201000099A (en) | 2008-06-20 | 2010-01-01 | Amgen Inc | S1P1 receptor agonists and use thereof |
MX2011004018A (es) * | 2008-10-14 | 2011-06-24 | Ning Xi | Compuestos y metodos de uso. |
MX2011011326A (es) * | 2009-04-27 | 2012-02-13 | Elan Pharm Inc | Antagonistas de piridinona de las integrinas alfa-4. |
CA2762680C (en) | 2009-05-21 | 2018-04-17 | Chlorion Pharma, Inc. | Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics |
MX2012002596A (es) * | 2009-09-03 | 2012-07-03 | Allergan Inc | Compuestos como moduladores de tirosina cinasas. |
US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
US8258158B2 (en) * | 2009-09-11 | 2012-09-04 | Hoffmann-La Roche Inc. | HSL inhibitors useful in the treatment of diabetes |
JP5795630B2 (ja) | 2010-04-29 | 2015-10-14 | デシフェラ ファーマシューティカルズ,エルエルシー | 抗癌及び抗増殖活性を示すシクロプロピルジカルボキサミド及び類似体 |
WO2011139891A1 (en) | 2010-04-29 | 2011-11-10 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites |
TW201204733A (en) * | 2010-06-25 | 2012-02-01 | Kowa Co | Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same |
EP4238566A1 (en) | 2012-05-02 | 2023-09-06 | Georgetown University | Treating amyotrophic lateral sclerosis with tyrosine kinase inhibitors |
WO2014038881A2 (ko) * | 2012-09-06 | 2014-03-13 | 씨제이제일제당 (주) | 피리돈 유도체를 포함하는 단백질 키나제 억제제 |
US9574135B2 (en) * | 2013-08-22 | 2017-02-21 | Nanoco Technologies Ltd. | Gas phase enhancement of emission color quality in solid state LEDs |
BR112016021383A2 (pt) | 2014-03-24 | 2017-10-03 | Genentech Inc | Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo |
WO2015162515A1 (en) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
US20190262323A1 (en) * | 2016-10-31 | 2019-08-29 | Georgetown University | Compositions and methods for treating neurodegenerative disorders |
EA039189B1 (ru) | 2017-05-11 | 2021-12-15 | Бристол-Маерс Сквибб Компани | Тиенопиридины и бензотиофены в качестве ингибиторов irak4 |
CN109206435B (zh) * | 2017-06-29 | 2020-09-08 | 中国医药研究开发中心有限公司 | 噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途 |
US11447500B2 (en) | 2018-03-08 | 2022-09-20 | Wellmarker Bio Co., Ltd. | Thienopyridine derivatives and pharmaceutical composition comprising same |
WO2021025407A1 (ko) * | 2019-08-02 | 2021-02-11 | 웰마커바이오 주식회사 | 옥소-피리딘 융합고리 유도체 및 이를 포함하는 약학적 조성물 |
KR20220059386A (ko) * | 2019-09-06 | 2022-05-10 | 웰마커바이오 주식회사 | 바이오마커 기반 치료용 조성물 |
JP7434575B2 (ja) | 2020-01-07 | 2024-02-20 | メッドシャイン ディスカバリー インコーポレイテッド | 重水素化チエノピリジン系化合物 |
CN115745999A (zh) * | 2021-11-19 | 2023-03-07 | 浙江奥洋新材料有限公司 | 一种可提高反应活性的纤维素碱性醚化、酯化反应溶剂叔丁五元二环胍的结构及其合成路线 |
CN115177618A (zh) * | 2022-07-26 | 2022-10-14 | 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) | Flt3抑制剂在制备治疗急性髓系白血病药物中的应用 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1280580A (zh) * | 1997-11-11 | 2001-01-17 | 辉瑞产品公司 | 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物 |
ATE277933T1 (de) * | 2000-06-06 | 2004-10-15 | Pfizer Prod Inc | Thiophenverbindungen zur verwendung als antikrebsmittel |
US20020004511A1 (en) * | 2000-06-28 | 2002-01-10 | Luzzio Michael Joseph | Thiophene derivatives useful as anticancer agents |
WO2003000194A2 (en) * | 2001-06-21 | 2003-01-03 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
DE60233736D1 (de) * | 2001-06-22 | 2009-10-29 | Kirin Pharma K K | Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung |
AU2002357193A1 (en) * | 2001-12-19 | 2003-07-09 | Smithkline Beecham Corporation | Thienopyrimidine compounds as protein tyrosine kinase inhibitors |
MXPA04008403A (es) * | 2002-03-01 | 2004-11-26 | Pfizer | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso. |
UA77303C2 (en) * | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
US7560558B2 (en) | 2002-08-23 | 2009-07-14 | Kirin Beer Kabushiki Kaisha | Compound having TGFβ inhibitory activity and medicinal composition containing the same |
CL2003002287A1 (es) * | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
CA2536788A1 (en) * | 2003-08-29 | 2005-03-10 | Pfizer Inc. | Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents |
JP2007504122A (ja) * | 2003-08-29 | 2007-03-01 | ファイザー・インク | 新規抗血管形成剤として有用なチエノピリジン−フェニルアセトアミドおよびその誘導体 |
ATE517091T1 (de) * | 2003-09-26 | 2011-08-15 | Exelixis Inc | C-met-modulatoren und verwendungsverfahren |
WO2005080377A1 (ja) * | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
WO2005121125A1 (en) * | 2004-06-09 | 2005-12-22 | Pfizer Inc. | Ether-linked heteroaryl compounds |
JP5368701B2 (ja) | 2004-07-02 | 2013-12-18 | エクセリクシス、インコーポレイテッド | c−Metモジュレーター及び使用方法 |
EP1781664B1 (en) * | 2004-07-30 | 2013-09-04 | MethylGene Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
MX2007006230A (es) * | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer. |
AU2006229343A1 (en) * | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency |
US20080161305A1 (en) | 2005-04-06 | 2008-07-03 | Exelixis, Inc. | C-Met Modulators and Methods of Use |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
CA2608726C (en) * | 2005-05-20 | 2013-07-09 | Methylgene Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
EP1957498B1 (en) * | 2005-05-20 | 2017-02-15 | MethylGene Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
US7732613B2 (en) * | 2005-09-14 | 2010-06-08 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7998978B2 (en) * | 2006-05-01 | 2011-08-16 | Pfizer Inc. | Substituted 2-amino-fused heterocyclic compounds |
WO2008054674A2 (en) | 2006-10-31 | 2008-05-08 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
-
2007
- 2007-01-30 JP JP2008552481A patent/JP2009526761A/ja active Pending
- 2007-01-30 US US11/699,830 patent/US8003662B2/en active Active
- 2007-01-30 TW TW096103347A patent/TW200806675A/zh unknown
- 2007-01-30 EP EP07870652A patent/EP1989211A2/en not_active Withdrawn
- 2007-01-30 AR ARP070100391A patent/AR059246A1/es unknown
- 2007-01-30 CA CA002636242A patent/CA2636242A1/en not_active Abandoned
- 2007-01-30 CN CNA2007800026090A patent/CN101522687A/zh active Pending
- 2007-01-30 WO PCT/US2007/002352 patent/WO2008063202A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US8003662B2 (en) | 2011-08-23 |
CA2636242A1 (en) | 2008-05-29 |
EP1989211A2 (en) | 2008-11-12 |
WO2008063202A2 (en) | 2008-05-29 |
JP2009526761A (ja) | 2009-07-23 |
TW200806675A (en) | 2008-02-01 |
WO2008063202A3 (en) | 2009-01-22 |
US20070197537A1 (en) | 2007-08-23 |
CN101522687A (zh) | 2009-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR059246A1 (es) | Compuestos heterobiciclicos de tiofeno y metodos de uso | |
AR059887A1 (es) | Compuestos pirazolicos heterobiciclicos, composiciones farmaceuticas que los contienen, y usos en trastornos hiperproliferativos, tales como cancer | |
AR060632A1 (es) | Compuestos inhibidores de fosfoinositida 3- quinasa y metodos de uso | |
AR050788A1 (es) | Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa | |
PE20190509A1 (es) | 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas | |
AR053728A1 (es) | Pirimidinas condensadas como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia y composiciones farmaceuticas que las contienen en combinacion con otros agentes terapeuticos | |
PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
PE20091204A1 (es) | Derivados de 2-aminoquinolina como antagonistas del receptor de 5-ht5a | |
PE20210040A1 (es) | Moduladores de la via de estres integrada | |
CO5011121A1 (es) | Derivados de isotiazol utiles como agentes anticancerosos | |
AR067093A1 (es) | N-(2-(hetaril) arilsulfonamidas y n-(2-( heteraril) hetaril) arilsulfonamidas | |
PE20061298A1 (es) | Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c | |
PE20090493A1 (es) | DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
AR052682A1 (es) | DERIVADOS DE 5, 6, 7, 8 - TETRAHIDROTIEN[2, 3 - B]QUINOLINA uTILES PARA INHIBIR LA ACTIVIDAD DE QUINESINA DE KSP, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS. | |
AR050529A1 (es) | Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa | |
AR050274A1 (es) | Derivados triciclicos del indeno-pirrol como moduladores de la serotonina | |
PE20070016A1 (es) | Compuestos heterociclicos n-enlazados como antagonistas del receptor p2y1 | |
PE20091068A1 (es) | Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor | |
PE20060185A1 (es) | ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA | |
PE20061367A1 (es) | Nuevos derivados del fluoreno y composiciones que los contienen | |
AR064155A1 (es) | Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso | |
AR049319A1 (es) | Derivados de 6-heteroarilfenantridinas | |
AR068898A1 (es) | Compuestos de tienopirimidinas y pirazolopirimidina y su uso como inhibidores de mtor y pi3k | |
PE20060604A1 (es) | Derivados del tetrahidronaftaleno como agentes antiinflamatorios y procedimiento para su preparacion | |
PE20090714A1 (es) | Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |